Your session is about to expire
← Back to Search
Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody for Cancer
Study Summary
This trial is testing a new drug called Toripalimab to see if it is safe and effective for treating advanced cancers. The trial will also look at the drug's effects on the immune system and overall survival.
- Advanced Cancers
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any opportunities to join this medical trial at present?
"Unfortunately, this experiment is not in need of any more participants at the moment. It was first posted on March 14th 2018 and edited as recently as December 12th 2021. For those searching for related studies, there are 2381 investigations currently seeking cancer patients and 151 dedicated to Toripalimab's Recombinant Humanized anti-PD-1 Monoclonal Antibody that require volunteers."
How many participants is the research team looking to recruit for this investigation?
"At this moment, the inquiry is not actively accepting applicants. It was initially published on March 14th 2018 and last revised in December 12th 2021. If you are looking for other studies, 2381 cancer trials and 151 Toripalimab Recombinant Humanized anti-PD-1 Monoclonal Antibody experiments have positions open to enrollees."
Has Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody been sanctioned by the FDA?
"The scant data available on Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody's safety and efficacy led to a score of 1 in our internal assessment."
Has Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody been utilized in any previous studies?
"Toripalimab, a Recombinant Humanized anti-PD-1 Monoclonal Antibody, was first investigated in 2017 at Beijing Cancer Hospital. At this point there are 7 concluded trials and 151 ongoing ones, with many of the latter taking place at Baltimore's medical facilities."
Are multiple hospitals in the city hosting this research endeavor?
"This trial is accepting patients from approximately 13 medical facilities, including the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center in Baltimore, Sidney Kimmel Comprehensive Cancer Center in Sarasota, and Florida Cancer Specialists in Houston."
Share this study with friends
Copy Link
Messenger